Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan, China.
Questrom School of Business, Boston University, Boston, Massachusetts, USA.
Int J Cancer. 2024 Oct 1;155(7):1162-1171. doi: 10.1002/ijc.34990. Epub 2024 May 11.
Low-grade cervical intraepithelial neoplasia (CIN1) is an early stage of cervical cancer development. Previously, we reported that exposure to polycyclic aromatic hydrocarbons (PAHs) increases the risk of cervical precancerous lesions, especially in females with a high-risk human papillomavirus (HR-HPV) infection. However, the effects of PAHs on CIN1 progression remain unclear. A community-based prospective cohort study was conducted to evaluate the role of exposure to PAHs in the progression of CIN1. A total of 564 patients diagnosed with CIN1 were followed-up at 6, 12, and 24 months, post-diagnosis, to determine CIN1 reversion, persistence, and progression. Exposure to PAHs was determined by the urine 1-hydroxipayrene (1-OHP) level. Our results showed that the 1-OHP level was significantly higher in patients with CIN1 persistence/progression than in those with reversion (P < .05). High exposure to PAHs increased the risk of CIN1 persistence/progression, with hazard ratios (HR), 95% confidence intervals (CI) of (1.62, 1.24-2.67), (1.98, 1.42-2.75), and (2.37, 1.61-3.49) at 6, 12, and 24 months, post-diagnosis, respectively. The effect was enhanced with HR-HPV positivity, as determined at 6 (1.82, 1.24-2.67), 12 (3.02, 1.74-5.23), and 24 (2.51, 1.48-4.26) months, post-diagnosis. Moreover, the predictive value of exposure to PAHs for CIN1 persistence/progression was higher in HR-HPV-positive patients than in HR-HPV-negative patients. The results revealed that exposure to PAHs facilitated the malignant progression of CIN1 and hindered its reversal, particularly in patients with HR-HPV infection. Our findings provide novel insights into early prevention and intervention targeting the initiation and progression of cervical neoplasia.
低度宫颈上皮内瘤变(CIN1)是宫颈癌发展的早期阶段。此前,我们报道过接触多环芳烃(PAHs)会增加宫颈癌前病变的风险,尤其是在 HPV 高危型(HR-HPV)感染的女性中。然而,PAHs 对 CIN1 进展的影响尚不清楚。本研究开展了一项基于社区的前瞻性队列研究,旨在评估 PAHs 暴露在 CIN1 进展中的作用。共有 564 例 CIN1 患者在诊断后 6、12 和 24 个月进行随访,以确定 CIN1 逆转、持续存在和进展情况。PAHs 暴露通过尿液 1-羟基芘(1-OHP)水平来确定。我们的结果表明,持续存在/进展的 CIN1 患者的 1-OHP 水平显著高于逆转的患者(P<0.05)。高 PAHs 暴露增加了 CIN1 持续存在/进展的风险,6、12 和 24 个月时的风险比(HR)及其 95%置信区间(CI)分别为(1.62,1.24-2.67)、(1.98,1.42-2.75)和(2.37,1.61-3.49)。该效应在 HR-HPV 阳性时增强,6、12 和 24 个月时的 HR 分别为(1.82,1.24-2.67)、(3.02,1.74-5.23)和(2.51,1.48-4.26)。此外,PAHs 暴露对 HR-HPV 阳性患者的 CIN1 持续存在/进展的预测价值高于 HR-HPV 阴性患者。结果表明,PAHs 暴露促进了 CIN1 的恶性进展,阻碍了其逆转,尤其是在 HR-HPV 感染的患者中。我们的研究结果为宫颈癌前病变的早期预防和干预提供了新的见解。